Abstract:Background: The global burden of non-alcoholic fatty liver disease (NAFLD) is growing, but its subsequent health consequences have not been thoroughly examined. We performed phenome-wide Mendelian randomization and disease-trajectory analyses to comprehensively assess the health outcomes of NAFLD.Methods: PheWAS analyses were conducted to map the associations of NAFLD with a broad range of phenotypes among 475,554 European in UK Biobank. Disease-trajectory and comorbidity analyses were applied to visualize the sequential patterns of multiple comorbidities related to the occurrence of NAFLD. The associations jointly verified by observational and polygenic PheWAS analyses were further replicated by two-sample MR analysis using data from the FinnGen study and international consortia.Findings: PheWAS analyses including 1,172 disease outcomes revealed the associations of NAFLD diagnosis (n=9,035) with intrahepatic (e.g., cirrhosis, liver abscess and liver cancer) and extrahepatic diseases, including circulatory diseases (i.e., various cardiac diseases, hypertension and cerebrovascular diseases), metabolic diseases (i.e., hyperlipidemia and diabetes mellitus), genitourinary system diseases (i.e., renal failure), neurological disorders (i.e., dementias and Alzheimer's disease), gastrointestinal diseases (i.e., gastritis, duodenitis and ulcerative colitis, stomach cancer and other malignant digestive neoplasms) and hematologic diseases (i.e., iron deficiency anemia and thrombocytopenia). Disease-trajectory and comorbidity network analyses identified 3 major extrahepatic comorbidities clusters related to NAFLD, mainly in cardiovascular, metabolic, and inflammatory diseases. Two-sample MR analyses supported the causal associations between NAFLD and the risk of several intrahepatic disorders, metabolic diseases, cardio-cerebro-vascular disease and ascites, but found no associations with neurological diseases (i.e., dementia).Interpretation: A prior diagnosis of NAFLD was associated with an increased risk of various extrahepatic diseases of circulatory, metabolic, genitourinary, gastrointestinal and possibly neurological systems. Three major sequential patterns of comorbidities related to NAFLD were identified, mainly in cardiovascular, metabolic and inflammatory diseases, contributing to development of combination interventions targeting distinct pathways for the health promotion among NAFLD patients.Funding: XL: the Natural Science Fund for Distinguished Young Scholars of Zhejiang Province (LR22H260001) and the National Nature Science Foundation of China (N0. 82204019); SCL: the Swedish Heart-Lung Foundation (Hjärt-Lungfonden, 20210351), the Swedish Research Council (Vetenskapsrådet, 2019-00977), and the Swedish Cancer Society (Cancerfonden).Declaration of Interest: All authors report no potential conflicts of interest.Ethical Approval: Ethical approval was granted by the UK Biobank by the North West-Haydock Research Ethics Committee (REC reference: 16/NW/0274).

PNPLA3 I148M Variant Affects Non-Alcoholic Fatty Liver Disease in Liver Transplant Recipients

Extrahepatic Organs in the Development of Non-Alcoholic Fatty Liver Disease in Liver Transplant Patients.

I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders

Extrahepatic organs in the development of non-alcoholic fatty liver disease in liver transplant patients

Genetic Variation in PNPLA3 Confers Susceptibility to Nonalcoholic Fatty Liver Disease

The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes

The rs2294918 E434K variant modulates PNPLA3 expression and liver damage.

Impact of PNPLA3 in Lean Individuals and in Cryptogenic Steatotic Liver Disease

The PNPLA3 Rs738409 C>G Variant Influences the Association Between Low Skeletal Muscle Mass and NAFLD: the Shanghai Changfeng Study

Genetic Variant I148M in PNPLA3 is Associated with the Ultrasonography-Determined Steatosis Degree in a Chinese Population.

Global Epidemiological Impact of PNPLA3 I148M on Liver Disease

Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype

A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease

Abstract 13791: Non-Alcoholic Fatty Liver Disease Risk SNP Variants Affect Lipid Metabolism

PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic-associated steatotic liver disease

The greater impact of PNPLA3 polymorphism on liver-related events in Japanese non-alcoholic fatty liver disease patients: A multicentre cohort study

NAFLD‐related gene polymorphisms and all‐cause and cause‐specific mortality in an Asian population: the Shanghai Changfeng Study

Multisystem Health Comorbidity Networks of Nonalcoholic Fatty Liver Disease: Phenome-Wide Mendelian Randomization and Disease-Trajectory Analyses

PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date

Genome-Wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits

Liver Cirrhosis as the Outcome of Non-Alcoholic Fatty Liver Disease Associated with PNPLA3 Gene RS738409 Polymorphism